Allogeneic Invariant Natural Killer T-cells agenT-797 clinical trials
Also written agenT-797.
Its developmentBy Agenus, MiNK Therapeutics and ImmunityBio, step by step5 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.How each study uses Allogeneic Invariant Natural Killer T-cells agenT-797 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Allogeneic Invariant Natural Killer T-cells agenT-797 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- agenT-797
- 7
Studies by the year they started
8 studies that test it; most in 2026 (4)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 3
MiNK Therapeutics (4) · Memorial Sloan Kettering Cancer Center (1) · University of Wisconsin, Madison (1) · Darren Sigal, MD (1) · ImmunityBio, Inc. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Allogeneic Invariant Natural Killer T-cells agenT-797.
- Jun 2027A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory FailurePhase 2 · MiNK Therapeutics
- Aug 2027A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction CancerPhase 2 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses Allogeneic Invariant Natural Killer T-cells agenT-797 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Allogeneic iNKT Cell Therapy (agenT-797) After SCTRecruitingPhase 1University of Wisconsin, MadisonNCT07758218Written as agenT-797
- BAL/BOT/agenT-797 in pMMR CRC With Liver MetastasesRecruitingPhase 2Darren Sigal, MDNCT07550088Written as agenT-797
- A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory FailureRecruitingPhase 2MiNK TherapeuticsNCT07615010Written as agenT-797
- A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction CancerActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06251973Written as AgenT-797
- Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)WithdrawnPhase 2ImmunityBio, Inc.NCT07492888Written as Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)
- A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDSCompletedPhase 1MiNK TherapeuticsNCT04582201Written as agenT-797
- A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid TumorsCompletedPhase 1MiNK TherapeuticsNCT05108623Written as agenT-797
- agenT-797 in Participants With Relapsed/Refractory Multiple MyelomaCompletedPhase 1MiNK TherapeuticsNCT04754100Written as agenT-797
What changed recently
From the registry's own updates since Oct 19, 2026.
Started recruiting1
- Allogeneic iNKT Cell Therapy (agenT-797) After SCTNov 12, 2026NCT07758218